Trials / Active Not Recruiting
Active Not RecruitingNCT05642780
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Klus Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SKB264 | be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle; |
| DRUG | Pembrolizumab | be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle; |
Timeline
- Start date
- 2023-01-17
- Primary completion
- 2027-11-30
- Completion
- 2027-12-31
- First posted
- 2022-12-08
- Last updated
- 2025-10-14
Locations
48 sites across 6 countries: United States, Australia, Belgium, Canada, China, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05642780. Inclusion in this directory is not an endorsement.